Summary
We have been investigating the use of cross-linked divalent (DFM) and trivalent (TFM) versions of the anti-carcinoembryonic antigen (CEA) monoclonal antibody A5B7 as possible alternatives to the parent forms (IgG and F(ab′)2) which have been used previously in clinical radioimmunotherapy (RIT) studies in colorectal carcinoma. Comparative biodistribution studies of similar sized DFM and F(ab′)2 and TFM and IgG, radiolabelled with both 131I and 90Y have been described previously using the human colorectal tumour LS174T nude mouse xenograft model (Casey et al (1996) Br J Cancer 74: 1397–1405). In this study quantitative estimates of radiation distribution and RIT in the xenograft model provided more insight into selecting the most suitable combination for future RIT. Radiation doses were significantly higher in all tissues when antibodies were labelled with 90Y. Major contributing organs were the kidneys, liver and spleen. The extremely high absorbed dose to the kidneys on injection of 90Y-labelled DFM and F(ab′)2 as a result of accumulation of the radiometal would result in extremely high toxicity. These combinations are clearly unsuitable for RIT. Cumulative dose of 90Y-TFM to the kidney was 3 times lower than the divalent forms but still twice as high as for 90Y-IgG. TFM clears faster from the blood than IgG, producing higher tumour to blood ratios. Therefore when considering only the tumour to blood ratios of the total absorbed dose, the data suggests that TFM would be the most suitable candidate. However, when corrected for equitoxic blood levels, doses to normal tissues for TFM were approximately twice the level of IgG, producing a two-fold increase in the overall tumour to normal tissue ratio. In addition RIT revealed that for a similar level of toxicity and half the administered activity, 90Y-IgG produced a greater therapeutic response. This suggests that the most promising A5B7 antibody form with the radionuclide 90Y may be IgG. Dosimetry analysis revealed that the tumour to normal tissue ratios were greater for all 131I-labelled antibodies. This suggests that 131I may be a more suitable radionuclide for RIT, in terms of lower toxicity to normal tissues. The highest tumour to blood dose and tumour to normal tissue ratio at equitoxic blood levels was 131I-labelled DFM, suggesting that 131I-DFM may be best combination of antibody and radionuclide for A5B7. The dosimetry estimates were in agreement with RIT results in that twice the activity of 131I-DFM must be administered to produce a similar therapeutic effect as 131I-TFM. The toxicity in this therapy experiment was minimal and further experiments at higher doses are required to observe if there would be any advantage of a higher initial dose rate for 131I-DFM.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Antoniw, P, Farnsworth, APH, Turner, A, Haines, AMR, Mountain, A, Mackintosh, J, Shochat, D, Humm, J, Welt, S, Old, LJ, Yarranton, GT & King, DJ (1996). Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and tri-Fab (TFM). Br J Cancer 74: 513–524.
Behr, TM, Sharkey, RM, Juweid, MI, Dunn, RM, Zhiliang, Y, Zhang, CH, Siegal, JA, Gold, DV & Goldenberg, DM (1995). Reduction of the renal uptake of radiolabelled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55: 3825–3834.
Buchsbaum, DJ & Order, SE (1990). Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 3: 213–233.
Boxer, GM, Chester, KA, Robson, L, Keep, PA, Casey, JL & Begent, RHJ (1995). Non-cross reactive scFv anti-CEA antibody from a combinatorial bacteriophage library. Br J Cancer Suppl: P139 (Abstract 59).
Casey, JL, King, DJ, Chaplin, LC, Haines, AMR, Pedley, RB, Mountain, A, Yarranton, GT & Begent, RHJ (1996). Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab′ fragments. Br J Cancer 74: 1397–1405.
DePalatis, LR, Frazier, KA, Cheng, RC & Kotite, NJ (1995). Lysine reduces renal accumulation of radioactivity associated with injection of the (177Lu) a-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 radioimmunoconjugate. Cancer Res 55: 5288–5295.
Durbin, PW, Jeung, N, Kullgren, B & Clemons, GK (1992). Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 63: 427–442.
Fawwaz, RA, Wang, TST, Srivastava, SC & Hardy, MA (1986). The use of radionuclides for tumour therapy. Nucl Med Biol 13: 429–436.
Flynn, AA, Green, AJ, Boxer, GM, Pedley, RB & Begent, RHJ (1998). A dosimetry model for the accurate characterisation of absorbed dose in mouse organs. Br J Cancer 78: 39
Fowler, JF (1990). Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiation Oncology Biol Phys 18: 1261–1269.
Ghetie, V, Poror, S, Borjak, J, Radu, C & Matesoid, D (1997). Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotech 15: 637–640.
Harrison, A, Walker, CA, Parker, D, Jankowski, KJ, Cox, JPL, Craig, AS, Sansom, JM, Beeley, NRA, Boyce, RA, Chaplin, L, Eaton, AW, Farnsworth, APH, Millar, K, Millican, AT, Randall, AM, Rhind, SK, Secher, DS & Turner, A (1991). The in vivo release of 90Y from cyclic and acyclic ligand antibody conjugates. Nucleic Med Biol 18: 469–476.
Johnson, RF, Pickett, SC & Barker, DL (1990). Autoradiography using phosphor technology. Electrophoresis 11: 355–360.
King, DJ, Turner, A, Farnsworth, APH, Adair, JR, Owens, RJ, Pedley, RB, Baldock, D, Proudfoot, KA, Lawson, ADG, Beeley, NRA, Millar, K, Millican, A, Boyce, BA, Antoniw, P, Mountain, A, Begent, RHJ, Shochat, D & Yarranton, GT (1994). Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54: 6176–6185.
King, DJ, Antonwi, P, Owens, RJ, Adair, JR, Haines, AMR, Farnsworth, APH, Finney, H, Lawson, ADG, Lyons, A, Baker, TS, Baldock, D, Mackintosh, J, Gofton, C, Yarranton, GT, McWilliams, W, Shochat, D, Leichner, PK, Welt, S, Old, LJ & Mountain, A (1995). Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 72: 1364–1372.
Kobayashi, H, Yoo, TM, Kim, IS, Kim, MK, Le, N, Webber, KO, Pastan, I, Paik, CH, Eckelman, WC & Carrasquillo, JA (1996). L-Lysine effectively blocks renal uptake of 125I or 99mTc-labelled anti-Tac disulphide stabilised Fv fragment. Cancer Res 56: 3788–3795.
Kobayashi, H, Nhat, L, Kim, IS, Kim, MK, Pie, JE, Palik, DS, Waldmann, TA, Paik, CH & Carrasquillo, JA (1999). The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res 59: 422–430.
Lane, DM, Eagle, KF, Begent, RHJ, Hope-Stone, LD, Green, AJ, Casey, JL, Keep, PA, Kelly, AMB, Ledermann, JA, Glaser, MG & Hilson, AJW (1994). Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 70: 521–525.
Pedley, RB, Boden, JA, Boden, RW, Green, A, Boxer, GM & Bagshawe, KD (1989). The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model. Br J Cancer 60: 549–554.
Pedley, RB, Boden, JA, Boden, R, Dale, R & Begent, RHJ (1993). Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 68: 69–73.
Pedley, RB, Boden, JA, Boden, R, Boxer, GM, Flynn, AA, Keep, PA & Begent, RHJ (1996). Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow-modifying agents. Cancer Res 56: 3293–3300.
Press, OW, Shan, D, Howell-Clarke, J, Eary, J, Applebaum, FR, Matthews, D, King, DJ, Haines, AMR, Hamann, P, Hinmann, L, Shochat, D & Bernstein, ID (1996). Comparative metabolism and retention of Iodine-125, Yttrium-90, and Indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56: 2123–2129.
Schott, ME, Milenic, DE, Yokota, T, Whitlow, M, Wood, JF, Fordyce, WA, Cheng, RC & Schlom, J (1992). Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single chain Fv molecules. Cancer Res 52: 6413–6417.
Sharkey, RM, Motta-Hennessy, C, Pawlyk, D, Siegal, JA & Goldenberg, DM (1990). Biodistribution and radiation dose estimates for Yttrium and Iodine-labelled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumour xenografts. Cancer Res 50: 2330–2336.
Siegel, JA, Wessels, BW, Watson, EE, Stabin, MG, Vriesendorp, HM, Bradley, EW, Badger, CC, Brill, AB, Kwok, CS, Stickly, DR, Eckerman, KF, Fisher, DR, Buchsbaum, DJ & Order, SE (1990). Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody, Immunoconj Radiopharm 3: 213–233.
Sumpio, BE & Hayslett, JP (1985). Renal handling of proteins in normal and disease states. Quart J Med 57: 611–635.
Sung, C, Shockley, TR, Morrison, PF, Dvorak, HF, Yarmush, ML & Dedrick, RL (1992). Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumours. Cancer Res 52: 377–384.
Tarburton, JP, Halpern, SE, Hagan, PL, Sudora, E, Chen, A, Fridman, DM & Pfaff, AE (1990). Effect of acetylation on monoclonal antibody ZCE-025 Fab′: Distribution in normal and tumour bearing mice. J Biol Resp Mod 9: 221–230.
Yokota, T, Milenic, DE, Whitlow, M & Schlom, J (1992). Rapid tumour penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402–3408.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Casey, J., Pedley, R., King, D. et al. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab′ fragments. Br J Cancer 81, 972–980 (1999). https://doi.org/10.1038/sj.bjc.6690795
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690795
Keywords
This article is cited by
-
Design of multivalent complexes using the barnase·barstar module
Nature Biotechnology (2003)